GlassScriptPhysician profile
Anne M Lent
NPI 1477630705
$1,181.21
in general payments reported to CMS, 2019-2025
16 companies · $376 in 2025
The $376 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $73.52 · 2021: $170 · 2022: $59.99 · 2023: $102 · 2024: $224 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $702.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $390.09 | 2020-2025 | Tezspire, Fasenra, Breztri |
| Novartis Pharmaceuticals Corporation | $195.99 | 2019-2025 | |
| Genzyme Corporation | $162.86 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $138.28 | 2025 | Dupixent |
| Galderma Laboratories, L.P. | $45.74 | 2025 | Nemluvio |
| Genentech USA, INC. | $37.43 | 2024 | Xolair |
| Kaleo, INC. | $33.24 | 2023-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $30.71 | 2024 | Eohilia |
| Blueprint Medicines Corporation | $24.99 | 2023 | |
| Urogen Pharma, INC. | $22.95 | 2023 | Jelmyto |
| Pfizer INC. | $21.78 | 2024 | |
| Biocryst US Sales Co., LLC | $19.31 | 2022 | |
| Optinose US, INC. | $18.03 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.49 | 2024 | |
| Phadia US INC. | $14.41 | 2023 | Immunocap |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bio Products Laboratory USA, INC. | $9.91 | 2023 | Gammaplex, Coagadex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Lent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.